Drugmakers will discontinue the sales of a controversial class of fentanyl-based painkillers by the end of September, the FDA confirmed Sept. 16.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Drugmakers will discontinue the sales of a controversial class of fentanyl-based painkillers by the end of September, the FDA confirmed Sept. 16.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis